Summit Therapeutics (SMMT) Share-based Compensation (2017 - 2026)
Summit Therapeutics' (SMMT) quarterly Share-based Compensation came in at $68.7 million in Q2 2026, down 85.65% YoY from $478.8 million in Q2 2025, and down 5.61% on a QoQ basis from $72.8 million in Q1 2026.
Summit Therapeutics (SMMT) Share-based Compensation (2017 - 2026) Analysis & Trends
Summit Therapeutics (SMMT) has 10 years of Share-based Compensation data on file, last reported at $68.7 million in Q2 2026.
- Quarterly Share-based Compensation fell 85.65% year-over-year to $68.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $384.0 million (down 26.18% YoY) and the FY2025 annual result came in at $732.4 million, up 1336.65% from the prior year.
- Share-based Compensation fell to $68.7 million in Q2 2026, from $72.8 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $478.8 million in Q2 2025 to a low of $705000.0 in Q3 2023.
- A 5-year average of $53.0 million and a median of $10.3 million in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2025 — Share-based Compensation surged 4218.04% — and 2026, when it sank 85.65%.
- Tracing SMMT's Share-based Compensation over 5 years: stood at $2.7 million in 2022, then jumped by 229.31% to $8.8 million in 2023, then advanced by 25.84% to $11.0 million in 2024, then surged by 914.79% to $111.8 million in 2025, then sank by 38.53% to $68.7 million in 2026.
- The last three Share-based Compensation figures came in at $68.7 million (Q2 2026), $72.8 million (Q1 2026), and $111.8 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | 68.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 68.71 Mn |
| Jun 30, 2026 | 68.71 Mn |
| Mar 31, 2026 | 72.79 Mn |
| Mar 31, 2026 | 72.79 Mn |
| Dec 31, 2025 | 111.78 Mn |
| Dec 31, 2025 | 111.78 Mn |
| Sep 30, 2025 | 130.76 Mn |
| Sep 30, 2025 | 130.76 Mn |
| Jun 30, 2025 | 478.78 Mn |
| Jun 30, 2025 | 478.78 Mn |
| Mar 31, 2025 | 11.10 Mn |
| Mar 31, 2025 | 11.10 Mn |
| Dec 31, 2024 | 11.02 Mn |
| Dec 31, 2024 | 11.02 Mn |
| Sep 30, 2024 | 19.37 Mn |
| Sep 30, 2024 | 19.37 Mn |
| Jun 30, 2024 | 11.09 Mn |
| Jun 30, 2024 | 11.09 Mn |
| Mar 31, 2024 | 9.51 Mn |
| Mar 31, 2024 | 9.51 Mn |